Adjuvant Everolimus Falls Short in High-Risk Renal Cancer
Adjuvant everolimus (Afinitor) failed to significantly improve recurrence-free survival (RFS) in patients with renal cell carcinoma (RCC) who were at high risk for recurrence after nephrectomy, according to results from a randomized phase III trial. The so-called EVEREST study showed that among 1,545 patients with histologically confirmed RCC who had undergone a full surgical resection, […]
Adjuvant Pembrolizumab Boosts Recurrence-Free Survival in High-Risk Melanoma
Adjuvant pembrolizumab (Keytruda) for resected stage II melanoma significantly prolonged recurrence-free survival (RFS) compared with placebo, according to results from the KEYNOTE-716 trial. At a median follow-up of 14.4 months, pembrolizumab for resected stage IIB and IIC melanoma decreased the risk of disease recurrence or death by 35% compared with placebo (hazard ratio 0.65, 95% […]